Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Research on γ-photon scattering correction method based on R-SSS algorithm.

Scientific reports·2026
Same author

HCGT-PL: a heterogeneous contrastive graph transformer unifying protein-ligand affinity prediction and structure-based virtual screening.

Chemical science·2026
Same author

Molecular Cobaloxime Engineering on 2D Fullerene Nanosheets Enables Enhanced Photocatalytic CO<sub>2</sub> Conversion.

ACS nano·2026
Same author

Utility of 3D Imaging in the Objective Evaluation of Glabellar Lines Following Botulinum Toxin Treatment.

Diagnostics (Basel, Switzerland)·2026
Same author

Earthworm gut microbiome promotes biodegradation of albendazole in soil.

Crop health·2026
Same author

Retraction notice to 'Insights into tolerance mechanisms of earthworms (Eisenia fetida) in copper-contaminated soils by integrating multi-omics analyses' [Environ. Res. 252 (2024) 118910].

Environmental research·2026

Related Experiment Video

Updated: May 8, 2026

Isolation, Culture, and Characterization of Primary Dermal Fibroblasts from Human Keloid Tissue
04:41

Isolation, Culture, and Characterization of Primary Dermal Fibroblasts from Human Keloid Tissue

Published on: July 28, 2023

Pharmacological treatment for keloids.

Chenyu Huang1, Rei Ogawa

  • 1Nippon Medical School, Department of Plastic, Reconstructive and Aesthetic Surgery, Tokyo , 1-1-5 Sendagi Bunkyo-ku , Japan +81 3 5814 6208 ; +81 3 5685 3076 ; r.ogawa@nms.ac.jp.

Expert Opinion on Pharmacotherapy
|August 14, 2013
PubMed
Summary

Keloid treatments are being developed based on various hypotheses of their cause. However, effective and specific pharmaceutical interventions for keloids remain elusive due to unclear etiology.

More Related Videos

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
08:20

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding

Published on: May 1, 2020

Related Experiment Videos

Last Updated: May 8, 2026

Isolation, Culture, and Characterization of Primary Dermal Fibroblasts from Human Keloid Tissue
04:41

Isolation, Culture, and Characterization of Primary Dermal Fibroblasts from Human Keloid Tissue

Published on: July 28, 2023

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
08:20

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding

Published on: May 1, 2020

Area of Science:

  • Dermatology
  • Pharmacology
  • Fibroproliferative Disorders

Background:

  • Keloids are characterized by excessive collagen and fibroblast accumulation.
  • Clinical symptoms include itching, invasiveness, and recurrence.
  • Current research focuses on developing new drugs and expanding indications for existing ones.

Purpose of the Study:

  • To review current pharmacological interventions for keloids.
  • To discuss drugs targeting keloid etiology and constituents.
  • To highlight the need for more robust clinical trials.

Main Methods:

  • Review of pharmacological interventions based on keloid etiology hypotheses.
  • Categorization of drugs targeting keloid components and microenvironment.
  • Analysis of current treatment limitations.

Main Results:

  • Interventions reviewed include ACE inhibitors, calcium-channel blockers, SERMs, vitamins, essential fatty acids, and transglutaminase inhibitors.
  • Drugs targeting extracellular matrix, cellular constituents, growth factors, and immunomodulators are discussed.
  • Current treatments lack specificity and efficiency.

Conclusions:

  • The unclear etiology and lack of animal models hinder the development of effective keloid treatments.
  • Large-scale, randomized, controlled clinical trials are essential to validate current data and improve reliability.
  • More research is needed for efficient, reliable, and specific pharmaceutical interventions for keloids.